Cistanche

Cistanche: A Comprehensive Reference Article

1. Identity and Botanical Description

Cistanche is a genus of holoparasitic desert plants belonging to the family Orobanchaceae. Cistanche is a Eurasian and African genus of holoparasitic desert plants in the family Orobanchaceae; the plants lack chlorophyll entirely and obtain nutrients and water from the host plants whose roots they parasitize, and are often called desert hyacinths. There are between 20 and 30 species of Cistanche, distributed from the Mediterranean region and North Africa through the Middle East to China.

The genus contains several medically relevant species. C. deserticola Y.C. Ma is an endangered species restricted to sandy deserts in Mongolia and northern China (Inner Mongolia, Xinjiang, Gansu), where it parasitizes the roots of Haloxylon ammodendron. Cistanche tubulosa is an obligate root holoparasite that primarily attaches to the roots of xerophytic desert shrubs, including Tamarix chinensis, Capparis decidua, Calligonum polygonoides, Calotropis procera, and Tamarix indica, using specialized haustoria for nutrient and water uptake. These haustoria form upon seed germination near the host root surface, penetrating the host's metaxylem to ramify into the vascular tissue; the plant is achlorophyllous and entirely lacks photosynthetic capacity.

The genus Cistanche Hoffmg. et Link is a holoparasitic desert genus belonging to the Orobanchaceae family and has 22 species throughout the world; the perennial parasite herbs commonly attach themselves to the roots of sand-fixing plants such as Haloxylon and Tamarix. The plant has a unique morphology: its stem is fleshy, cylindrical, and can grow up to 100 cm in height, with no true leaves — instead it has scale-like bracts arranged spirally along the stem. The flowers are purplish-red or yellowish, blooming from May to June, and the fruit is a capsule containing numerous tiny seeds.

The two species of primary medicinal and commercial importance are Cistanche deserticola Y.C. Ma and Cistanche tubulosa (Schenk) Wight. In 2000, C. deserticola was recorded in the Chinese Pharmacopoeia, and C. tubulosa was added to the Chinese Pharmacopoeia in 2005 as an alternative. Additional species studied to a lesser degree include C. salsa, C. sinensis, and C. phelypaea.

In Traditional Chinese Medicine (TCM), the herb is known as Rou Cong-Rong (肉苁蓉). Among all the tonics in TCM, Herba Cistanche is widely accepted as a superior one and has even been given the name "Ginseng of the Deserts." The medicinal part used is the dried fleshy stem, harvested before flowering.

Regarding conservation status: Cistanche deserticola has been placed on CITES Appendix II, a list of species not banned from trade but requiring monitoring; with increased consumption, the population of the species has decreased and its area of distribution has shrunk. Cistanche tubulosa has largely supplanted C. deserticola in commerce due to cultivability and relative abundance.

Common Preparations and Forms

• Dried crude herb (raw slices): The fleshy stems are sliced and dried for use in decoctions. Traditional processing often involves wine-soaking (wine-processed cistanche, or jiu cong rong), steaming, or salt-processing.
• Standardized extracts: Concentrated powdered or liquid extracts, often standardized to a minimum percentage of phenylethanoid glycosides (PhGs) — particularly echinacoside — or total PhG content.
• Capsules and tablets: Including the pharmaceutical-grade product Memoregain® (Cistanche tubulosa glycoside capsules), studied in clinical trials for neurological conditions.
• Functional foods and beverages: In 2018, desert cistanche was included in the Catalog of Substances That Are Both Food and Chinese Medicinal Materials According to Tradition by China's National Health Commission, showing that cistanche can be used as a daily food for the health care of the general population.

Cistanche deserticola is one of the most precious plants used traditionally as a Chinese medicine and has recently been used in pharmaceutical and healthy food industries. Steaming and drying are two important steps in the processing of C. deserticola. The most chemical variation occurs during the steaming process; metabolic pathway analysis indicated that phenylpropanoid and flavonoid biosynthesis and alanine metabolism were observed during steaming.

2. Traditional and Historical Use

The uses of Herba Cistanche have evolved over nearly 2,000 years. Herba Cistanche was described in the oldest surviving herb classic, Shennong Bencao Jing (approximately 100 A.D.). Since then, it has been described in many famous traditional Chinese herb classics spanning different dynasties, including Yaoxinglun, The Compendium of Materia Medica (Bencaogangmu), and Benjingfengyuan.

The earliest written record of C. deserticola used for dietary health purposes appears in the Tang Dynasty text Supplement to Materia Medica. It was the most frequently prescribed drug against chronic renal disease in China for successive dynasties.

Within TCM, Herba Cistanche is applied as a tonic and/or in a formula for chronic renal disease, impotence, female infertility, morbid leucorrhea, profuse metrorrhagia, and senile constipation. In the framework of TCM theory, it is classified as warming and tonifying Kidney Yang, replenishing Jing (essence) and blood, and moistening the intestines to relieve constipation. Among traditional Chinese medicinal herbs used in formulations for anti-aging and longevity, it is second only to ginseng in usage frequency.

Across the classical literature, cistanche appears in pill and meal forms with herbs such as Cuscuta (Tu Si Zi), Eucommia (Du Zhong), Schisandra (Wu Wei Zi), Polygala (Yuan Zhi), and prepared Aconite (Fu Zi) to address "Kidney deficiency," "consumptive weakness," and elderly constipation.

Beyond China, cistanche species grow across a wide arid belt. Cistanche deserticola is mainly distributed in the regions of China (Xinjiang, Inner Mongolia, Gansu), Mongolia, Iran, and India. Use of allied species such as C. tubulosa was documented in traditional medicine across the Middle East and Central Asia for similar tonic and aphrodisiac purposes, reflecting the wide natural range of the genus.

3. Phytochemistry: Key Constituents and Active Compounds

The chemical constituents of Herba Cistanche mainly consist of volatile oils, non-volatile phenylethanoid glycosides (PhGs), iridoids, lignans, alditols, oligosaccharides, and polysaccharides. To date, more than 100 compounds have been isolated from this genus, including phenylethanoid glycosides, carbohydrates, lignans, iridoids, etc.

3.1 Phenylethanoid Glycosides (PhGs)

Phenylethanoid glycosides (PhGs), as the dominant bioactive components of Cistanche, are characterized by diverse chemical structures and prominent multi-target synergistic pharmacological activities. The principal PhGs are echinacoside, acteoside (verbascoside), cistanoside A, and, in C. tubulosa, compounds such as tubuloside B and isoacteoside. The chemical components cistanoside B, C, D, and E exist only in C. deserticola and release methylated hydroxytyrosol following metabolism.

Echinacoside (ECH) is one of the most representative PhGs and has considerable neuroprotective effects; it is an effective ingredient in numerous commercial drugs. Its complete biosynthetic pathway has been elucidated in Cistanche tubulosa. A distinct downstream assembly process from tyrosol to ECH involves sequential glucosylation, acylation, hydroxylation, and rhamnosylation to form acteoside, ending with a final glucosylation converting acteoside to ECH.

Echinacoside and acteoside are the two major PhG compounds and have been reported to improve glucose tolerance, promote cell proliferation and bone regeneration, and inhibit type I allergy.

Phenylethanoid glycosides have demonstrated wide pharmacological actions and have great clinical value, though challenges such as poor bioavailability, fast and extensive metabolism need to be addressed.

3.2 Polysaccharides

Modern pharmacological studies have demonstrated that polysaccharides are the primary active components of Cistanche alongside PhGs, exhibiting diverse pharmacological activities including immunomodulatory, antioxidant, anti-fatigue, and antitumor effects. Cistanche has been utilized globally as both a food and medicinal ingredient for centuries. The biological activities attributed to these polysaccharides encompass immunomodulatory effects, anti-aging properties, anti-osteoporosis activity, neuroprotection, anti-tumor effects, as well as protective activities for the gastrointestinal tract and liver.

Polysaccharides can play a role in immunomodulation, antiviral, anti-cancer, hypoglycemic, prevention and treatment of heart disease, and laxative effects.

3.3 Iridoids

Iridoids are one of the main chemical constituent classes of cistanche and have antibacterial, anti-inflammatory, and analgesic effects. At present, 27 kinds of cycloen ether terpenoid (iridoid) active substances have been isolated from cistanche.

3.4 Lignans

Lignans represent another class of bioactive compounds isolated from Cistanche species. Compounds isolated from C. tubulosa include phenylethanoid glycosides, carbohydrates, lignans, iridoids, echinacoside, verbascoside, chlorogenic acid, acteoside, and luteoloside.

3.5 Other Constituents

Chemical analysis has indicated that various compounds, including essential oils, PhGs, iridoids, lignans, alditols, oligosaccharides, and polysaccharides are the main constituents; the total isolated non-volatile compounds number more than 100.

4. Mechanisms of Action

4.1 Antioxidant and Cytoprotective Mechanisms

PhGs exert anti-inflammatory, antioxidant, immunomodulatory, neuroprotective, antitumor, and hepatoprotective effects mainly by regulating multiple signaling pathways, such as NF-κB, MAPK, PI3K/Akt, and Nrf2/HO-1.

Echinacoside can reduce MDA content and improve the activities of SOD and GSH-Px in ischemic brain injury, and molecular docking analysis displays that echinacoside may bind to Keap-1, leading to Nrf-2 nuclear translocation. Acteoside has been shown to decrease infarct volume and brain water content to improve neurological deficits in ischemia-reperfusion (MCAO/R) rats through mitigation of oxidative stress.

In senescent human dermal fibroblasts, Cistanche deserticola polysaccharide (CDP) treatment increased cell proliferation and decreased the proportion of senescence-associated β-galactosidase-positive cells; the treatment suppressed the senescence-related secretory phenotype and reduced reactive oxygen species (ROS) production, alleviating H₂O₂-induced oxidative stress.

4.2 Neuroprotective Mechanisms

Echinacoside (ECH) is a natural phenylethanoid glycoside in Cistanche tubulosa; a large number of studies have shown that ECH has very promising potential in the inhibition of neurodegenerative disease progression. Experimental studies suggest that ECH exhibits a variety of beneficial effects on neuronal function, including protecting mitochondrial function, anti-oxidative stress, anti-inflammatory, anti-endoplasmic reticulum stress (ERS), and regulating autophagy.

Acteoside from Cistanche salsa was shown to inhibit neuronal cell death induced by MPP+ and glutamate; acteoside could protect cells from X-ray-induced damage through enhancing the scavenging activity of ROS, decreasing the Bax/Bcl-2 ratio, downregulating the activity of procaspase-3, and modulating the MAPK signaling pathway. Tubuloside B has neuroprotective effects against MPP+ toxicity by inhibiting MPP+-induced apoptosis and oxidative stress, and against TNF-α-induced apoptosis in SH-SY5Y cells via anti-oxidative stress effects, maintenance of mitochondrial function, and inhibition of caspase-3 activity.

4.3 Bone Metabolism Mechanisms

Chinese herbal medicine Cistanche deserticola can regulate bone metabolism by promoting osteoblast activity and inhibiting osteoclast activity, with low toxicity and adverse reactions. In ovariectomized rat models, cistanche treatment demonstrated enhanced trabecular morphology, denser bone structure, smaller bone marrow cavities, and elevated estradiol (E2), bone mineral density (BMD), and OPG levels compared to controls.

4.4 Immunomodulatory Mechanisms

Extracts of C. deserticola have been reported to antagonize immunosenescence in senescence-accelerated mouse prone 8 (SAM-P8) mice, increasing both naïve T and natural killer cell populations.

5. Scientific Evidence by Area of Use

5.1 Neurology: Neuroprotection and Cognitive Function

Neuroprotection is one of the most extensively researched areas of cistanche pharmacology. The neuroprotective efficacy of echinacoside has been investigated in the prevention and treatment of neurodegenerative diseases, including Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS), based on published data from both in vivo and in vitro studies.

Evidence strength: Predominantly preclinical (animal and cell models); one small uncontrolled human study.

The most significant human clinical evidence comes from a study of Memoregain®: An open-label, nonplacebo-controlled clinical study on Cistanche tubulosa glycosides evaluated the treatment of moderate AD. Each patient was administered two 300 mg Cistanche tubulosa glycoside capsules three times per day for 48 weeks. A total of 18 patients with AD were assessed for drug efficacy by ADAS-cog, MMSE, ADLs, Blessed Behavioral Scale, and CGI scales. The MMSE score was 14.78 ± 2.51 at baseline and 14.06 ± 4.26 at study completion. While changes in ADAS-cog score before and after 48 weeks were statistically insignificant, the score improved in 10 patients, deteriorated in 7, and remained unchanged in 1. ADL and CGI scores showed no significant difference from baseline, and all adverse reactions were mild. After treatment, patients showed no obvious aggravation of cognitive function; comparison with acetylcholinesterase inhibitors suggests Memoregain® has potential as an option for mild to moderate AD, but large trials with a bigger population are required to confirm.

On the preclinical side, a 2025 study in Frontiers in Pharmacology found that cistanche glycosides inhibit amyloid-beta aggregation and protect against neuronal apoptosis; cistanche glycosides improved spatial learning and memory in Alzheimer's model mice through gut microbiota remodeling and fatty acid metabolism regulation.

The 300 mg three-times-daily dosage regimen was selected because it had been approved by the State Food and Drug Administration in China for treating vascular dementia.

5.2 Fatigue and Physical Performance

Evidence strength: One randomized double-blind placebo-controlled human trial (combination product), limited to a combined botanical formula.

A pivotal human trial investigated a combined product: A botanical product containing cistanche (Cistanche tubulosa [Schenk] Wight) and ginkgo (Ginkgo biloba L.) extracts was evaluated in adults with chronic fatigue syndrome (CFS) in a randomized, double-blind, placebo-controlled clinical trial. A total of 190 subjects (35–60 years old, non-obese) with CFS were randomized to receive one tablet of a low dose (120-mg ginkgo and 300-mg cistanche), a high dose (180-mg ginkgo and 450-mg cistanche) or a placebo once daily for 60 days. Blood samples and responses on the Chalder fatigue scale (CFQ 11), the WHO quality-of-life questionnaire (WHOQOL), and the sexual life quality questionnaire (SLQQ) were collected at baseline and post-intervention. A key limitation of this study is that the product contained both cistanche and ginkgo, making it impossible to attribute observed effects to cistanche alone.

Pharmacological research showed that extracts from Cistanche plants possess a wide spectrum of activities, including increasing the ability to learn and memorize, treating AD, enhancing immunity, prolonging lifespan, as well as anti-aging and anti-fatigue effects. These broader claims, however, primarily rest on animal model data.

5.3 Sexual Health and Reproductive Function

Evidence strength: Predominantly animal model studies; no published randomized controlled human trials specifically on sexual function or testosterone as of the available literature.

Cistanches Herba is a famous traditional Chinese medicine that has been in use for treating kidney deficiency, impotence, female infertility, morbid leucorrhea, profuse metrorrhagia, and senile constipation.

Cistanche tubulosa (Schenk) Wight and Cistanche deserticola Ma are renowned Chinese herbal medicines abundant in diverse bioactive compounds that exhibit therapeutic effects on many diseases related to oxidative stress and disorders of sex hormone levels.

Various PhGs from C. tubulosa have been reported to exhibit anti-osteoporotic activity, vasorelaxation effects, protection from testis and sperm injury, and anti-hepatic fibrosis effects. These findings derive from in vitro and animal studies. Cistanche deserticola contains chemicals that act as antioxidants and also contains chemicals that might decrease swelling (inflammation), slow the breakdown of bones, and modify levels of hormones in the body. No large-scale randomized controlled human trials specifically evaluating sexual function endpoints have been identified in the peer-reviewed literature reviewed here.

5.4 Bone Health and Osteoporosis

Evidence strength: Animal model studies; no published human clinical trials specifically on bone endpoints.

Cistanche deserticola can regulate bone metabolism by promoting osteoblast activity and inhibiting osteoclast activity with low toxicity and adverse reactions. Therefore, Cistanche deserticola has attracted increasing attention for its efficacy in the prevention and treatment of osteoporosis.

Previous studies have demonstrated that C. deserticola has anti-osteoporotic activity, and in-depth studies have been conducted to explore the anti-osteoporotic activity and mechanisms of action of Cistanche deserticola polysaccharides (CDPs). The evidence base for bone effects is preclinical; well-controlled human trials are lacking.

5.5 Immunomodulation

Evidence strength: Primarily in vitro and animal studies.

Modern pharmacological studies have demonstrated that polysaccharides, as primary active components of Cistanche, exhibit immunomodulatory, antioxidant, anti-fatigue, and antitumor effects. The specific immunomodulatory mechanisms have been described in cell and animal studies involving regulation of lymphocyte populations and cytokine profiles. Direct human evidence for immune endpoints is not established in the available literature.

5.6 Constipation and Gastrointestinal Function

Evidence strength: Animal model data; traditional use well documented.

Cistanche deserticola Ma, a well-known traditional Chinese medicine, is frequently used to alleviate constipation. In a loperamide-induced mouse constipation model, Cistanche polysaccharides (CDPS) were investigated, and serum levels of inflammatory factors, gastrointestinal hormones, and neurotransmitters were measured; intestinal tight junction integrity and gut microbial community structure were assessed. The proposed mechanism involves modulation of intestinal barrier function and microbiota composition. Human clinical data specifically on constipation endpoints are limited.

5.7 Hepatoprotection

Evidence strength: In vitro and animal studies only.

The methanolic extract from fresh stems of Cistanche tubulosa (Orobanchaceae) was found to have hepatoprotective effects against D-galactosamine (DGalN)/lipopolysaccharide (LPS)-induced liver injury in mice. Cistanche deserticola polysaccharide (CDPs) possess pharmacological activities including hepatoprotective and anti-inflammatory effects, based on preclinical evidence.

5.8 Antitumor Effects

Evidence strength: In vitro and animal studies only; no human clinical evidence.

Recent studies showed that echinacoside and acteoside had anti-tumor effects on mouse skin melanoma cell line KML31; Cistanche tubulosa phenylethanoid glycosides (CTPG) also showed anti-tumor effects on mouse melanoma cell line B16-F10. These findings are preliminary and confined to cell and animal models.

5.9 Anti-aging Effects

Evidence strength: Preclinical; no large-scale human clinical trials demonstrating anti-aging effects.

Modern pharmacological studies have demonstrated that Herba Cistanches possesses broad medicinal functions, especially for use in anti-senescence, anti-oxidation, neuroprotection, anti-inflammation, hepatoprotection, immunomodulation, anti-neoplastic, anti-osteoporosis, and the promotion of bone formation. The anti-aging research is centered on oxidative stress pathways, mitochondrial protection, and telomere-related biology in animal models.

6. Dosage Forms and Reported Dosages

Dosages reported in specific studies and regulatory frameworks include the following:

• Memoregain® (Cistanche tubulosa glycoside capsules) — Alzheimer's disease study: Each patient was administered two 300 mg Cistanche tubulosa glycosides capsules three times per day for 48 weeks (total 1,800 mg/day of glycoside capsules). This dosage regimen was selected because it had been approved by the State Food and Drug Administration in China for treating vascular dementia.
• CFS combination trial — low dose: 120 mg ginkgo and 300 mg cistanche once daily for 60 days.
• CFS combination trial — high dose: 180 mg ginkgo and 450 mg cistanche once daily for 60 days.

No universally validated or pharmacopeially standardized daily dose has been established for general supplemental use. The Chinese Pharmacopoeia lists a conventional decoction dose for dried crude herb but specific standardized extract dosages vary by product and study. The processing method (wine-processed, steamed, or raw) significantly affects the chemical composition and thus the effective dose may differ between preparations.

7. Safety Considerations

7.1 Regulatory and Toxicological Status

In 2021, the European Food Safety Authority (EFSA) passed (EU) 2015/2283, which means that cistanche water extract PhG has the potential to enter EFSA's novel food list and it may have the opportunity to be produced in Europe as a food supplement and food for special medical purposes.

In 2018, desert cistanche was included in China's Catalog of Substances That Are Both Food and Chinese Medicinal Materials According to Tradition by the National Health Commission, showing that cistanche can be used as a daily food for the health care of the general population.

Genotoxicity and 28-day repeated dose toxicity tests have been conducted, and the findings provide evidence that cistanche has a certain degree of edible safety.

7.2 Adverse Effects Reported in Clinical Studies

In the Memoregain® Alzheimer's study, all adverse reactions were mild. After Memoregain® treatment, patients showed no obvious aggravation of cognitive function, independent living ability, or overall conditions, remaining stable throughout the study.

Gastrointestinal effects are the most consistently reported adverse events in clinical contexts. The laxative property of cistanche — one of its intended traditional uses — can manifest as an unwanted side effect at higher doses. Cistanche deserticola is frequently used in TCM to alleviate constipation, reflecting its established pharmacological activity on intestinal motility; individuals who do not have constipation may therefore experience loose stools.

7.3 Bioavailability Constraints

Phenylethanoid glycosides have demonstrated wide pharmacological actions but have challenges including poor bioavailability, fast and extensive metabolism, that need to be addressed to realize their clinical value. This means the in vivo pharmacological effects may differ substantially from those observed in cell culture experiments using high concentrations.

7.4 Species-Related Quality Considerations

The chemical components cistanoside B, C, D, and E exist only in C. deserticola and release methylated hydroxytyrosol following metabolism. This factor contributes to the metabolic difference between C. deserticola and C. tubulosa. Products derived from different species may therefore differ in their chemical profile and biological activity. There is no comparative study yet on the metabolites resulting from the traditional usage of Cistanche deserticola and C. tubulosa water extract, two species that are recorded in the Chinese Pharmacopoeia.

7.5 Conservation and Authenticity Concerns

Cistanche deserticola has been placed on CITES Appendix II; with increased consumption, the population of the species has decreased and its area of distribution has shrunk. This has driven a shift in commercial supply toward C. tubulosa and cultivated material, but it raises concerns about botanical authenticity in commercial products.

8. Research Landscape and Evidence Quality Overview

From 1980–2022, 443 Cistanche-themed publications were indexed on Web of Science, including 417 articles (94.13%), 21 reviews (4.74%), and 5 book chapters (1.13%). The cumulative number of citations to these publications was 7,958, at an average of 17.96 per paper. Annual publication statistics showed the number increased in three stages; after a slow rise between 1980 and 2003, the yearly number increased significantly in the following decade to reach 19 papers in 2012, and since then has increased steadily, expected to exceed 50 in 2022.

The overall evidence base for cistanche, despite this growing literature, is characterized by a heavy predominance of in vitro and animal studies. The crude extracts and isolated compounds have exhibited a wide range of in vitro and in vivo pharmacologic effects, such as neuroprotective, immunomodulatory, anti-inflammatory, hepatoprotection, anti-oxidative, anti-bacterial, and anti-tumor effects. However, robust, adequately powered, randomized, placebo-controlled human trials across most proposed indications remain limited. The Alzheimer's disease trial with Memoregain® represents the most clinically specific available human study, but was open-label and included only 18 subjects. The CFS trial was randomized and placebo-controlled but used a combination product, confounding attribution of effects to cistanche specifically. Across categories such as sexual function, hormonal modulation, bone health, and anti-aging, the evidence is essentially preclinical.

References

• Zhou S. et al. (2023). Analysis of the active ingredients and health applications of cistanche. Frontiers in Nutrition. PMC10042234.
• Wang T. et al. (2016). Herba Cistanche (Rou Cong-Rong): One of the Best Pharmaceutical Gifts of Traditional Chinese Medicine. Frontiers in Pharmacology. PMC4771771.
• Jiang Y. et al. (2018). Herba Cistanches: Anti-aging. Aging and Disease. PMC5758349.
• Phenylethanoid Glycosides from Cistanche deserticola Y. C. Ma: Synergistic Effects, Multi-target Mechanisms and Translational Applications. PMC12987270.
• Total Glycosides of Cistanche deserticola Promote Neurological Function Recovery by Inducing Neurovascular Regeneration via Nrf-2/Keap-1 Pathway in MCAO/R Rats. PMC7089931.
• Phenylethanoid Glycosides from Cistanche tubulosa Inhibits the Growth of B16-F10 Cells both in Vitro and in Vivo by Induction of Apoptosis via Mitochondria-dependent Pathway. PMC5039372.
• Therapeutic Potential and Molecular Mechanisms of Echinacoside in Neurodegenerative Diseases. PubMed PMID 35185590.
• Huang W. et al. (2025). Complete pathway elucidation of echinacoside in Cistanche tubulosa and de novo biosynthesis of phenylethanoid glycosides. Nature Communications.
• Cistanches Herba: An overview of its chemistry, pharmacology, and pharmacokinetics property. Journal of Ethnopharmacology. ScienceDirect.
• An Open-Label, Nonplacebo-Controlled Study on Cistanche tubulosa Glycoside Capsules (Memoregain®) for Treating Moderate Alzheimer's Disease. PMC10852647.
• Guo Q. et al. (2013). An open-label, nonplacebo-controlled study on Cistanche tubulosa glycoside capsules (Memoregain®) for treating moderate Alzheimer's Disease. American Journal of Alzheimer's Disease & Other Dementias. PubMed PMID 23687177.
• A Botanical Product Containing Cistanche and Ginkgo Extracts Potentially Improves Chronic Fatigue Syndrome Symptoms in Adults: A Randomized, Double-Blind, and Placebo-Controlled Study. PMC8662561.
• Cistanche deserticola polysaccharide alleviates constipation by regulating intestinal barrier function and intestinal microbiota and their metabolites. PMC11645619.
• Effectiveness of desertliving cistanche in managing hyperlipidemic osteoporosis in ovariectomized rats through the PI3K/AKT signaling pathway. PMC11225217.
• Cistanche Deserticola for Regulation of Bone Metabolism: Therapeutic Potential and Molecular Mechanisms on Postmenopausal Osteoporosis. PubMed PMID 35930138.
• Cistanche deserticola Polysaccharide Reduces Inflammation and Aging Phenotypes in the Dermal Fibroblasts through the Activation of the NRF2/HO-1 Pathway. PMC10647235.
• Studies on Cistanches Herba: A Bibliometric Analysis. PMC10005655.
• The role of Cistanches Herba and its ingredients in improving reproductive outcomes: A comprehensive review. PubMed PMID 38718638.
• Integrated analysis of phytochemical composition, pharmacokinetics, and network pharmacology to probe distinctions between the stems of Cistanche deserticola and C. tubulosa. PubMed PMID 35880684.
• Widely Targeted Metabolomics Analysis to Reveal Transformation Mechanism of Cistanche Deserticola Active Compounds During Steaming and Drying Processes. PMC8551385.
• Rapid screening and identification of the differences between metabolites of Cistanche deserticola and C. tubulosa water extract in rats by UPLC-Q-TOF-MS. PubMed PMID 27639339.
• Ecological modeling of Cistanche deserticola Y.C. Ma in Alxa, China. PMC6739506.
• An account of the genus Cistanche (Orobanchaceae) in Iraq and taxonomic considerations in the Middle East. PMC10918587.
• Extensive gene loss in the plastome of holoparasitic plant Cistanche tubulosa (Orobanchaceae). PMC7782945.
• Cistanche tubulosa glycosides ameliorate cognitive decline in APP/PS1 mice via modulation of gut microbiota and fatty acid metabolism. PMC12370757.
• Enhanced oral bioavailability of two Cistanche polysaccharides in acteoside: an in-depth analysis of intestinal flora, short-chain fatty acids, and pharmacokinetic regulation. PMC12083017.
• Safety assessment of the Cistanche tubulosa health food product Memoregain®: Genotoxicity and 28-day repeated dose toxicity test. Food and Chemical Toxicology. ScienceDirect.
• Cistanche deserticola improves postmenopausal osteoporosis through gut microbiota and short-chain fatty acids. International Journal of Biological Macromolecules. ScienceDirect.
• The potential, challenges, and prospects of polysaccharides from the genus Cistanche as therapeutic agents for aging-related diseases: A review. ScienceDirect.
• Therapeutic, nutritional benefits, and applications of Cistanche Deserticola Y.C.Ma: a systematic review. Food, Nutrition and Health. Springer Nature.
• Cistanche. Wikipedia. (For taxonomy/CITES status overview only.)